Literature DB >> 27876378

Toxicities and dose-volume histogram parameters of MRI-based brachytherapy for cervical cancer.

Youngkyong Kim1, Yeon-Joo Kim2, Joo-Young Kim3, Young Kyung Lim1, Chiyoung Jeong1, Jonghwi Jeong1, Meyoung Kim1, Myong Cheol Lim4, Sang-Soo Seo4, Sang-Yoon Park4.   

Abstract

PURPOSE: To analyze the toxicities and dose-volume histogram parameters of external-beam and magnetic resonance imaging-based intracavitary brachytherapy in cervical cancer patients. METHODS AND MATERIALS: Acute and late toxicities were assessed in 135 patients divided into four groups: group 1, grade 0; group 2, grades 1-4; group 3, grades 0-1; and group 4, grades 2-4. The doses at the International Commission on Radiation Units and Measurements (DICRU) and minimum doses to the most exposed 0.1, 1, 2, and 5 cc (D0.1cc, D1cc, D2cc, and D5cc) of normal organs were calculated as equivalent doses in 2 Gy (α/β = 3).
RESULTS: The median follow-up was 35.2 months. For rectum, DICRU, D0.1cc, D1cc, and D2cc were significantly different between groups 1 and 2 and DICRU, D0.1cc, and D1cc between groups 3 and 4. For bladder, D0.1cc, D1cc, and D2cc were significantly different between groups 1 and 2 and DICRU, D1cc, D2cc, and D5cc between groups 3 and 4. Grade 2-4 bladder toxicity occurred in fewer patients with D2cc ≤ 95 Gy than those with D2cc > 95 Gy (7% vs. 22%, p = 0.014).
CONCLUSIONS: DICRU, D0.1cc, D1cc, and D2cc are relevant for predicting late rectal toxicities. The patients with bladder D2cc > 95 Gy are required to be in close observation for severe late toxicities.
Copyright © 2016 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Cervical neoplasms; DVH parameters; Magnetic resonance imaging; Toxicity

Mesh:

Year:  2016        PMID: 27876378     DOI: 10.1016/j.brachy.2016.10.005

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  9 in total

1.  [Rectal toxicity prediction based on accurate rectal surface dose summation for cervical cancer radiotherapy].

Authors:  Jia-Wei Chen; Hai-Bin Chen; Qiang He; Yu-Liang Liao; Xin Zhen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-12-20

2.  Investigating rectal toxicity associated dosimetric features with deformable accumulated rectal surface dose maps for cervical cancer radiotherapy.

Authors:  Jiawei Chen; Haibin Chen; Zichun Zhong; Zhuoyu Wang; Brian Hrycushko; Linghong Zhou; Steve Jiang; Kevin Albuquerque; Xuejun Gu; Xin Zhen
Journal:  Radiat Oncol       Date:  2018-07-06       Impact factor: 3.481

3.  Dose constraints in the rectum and bladder following carbon-ion radiotherapy for uterus carcinoma: a retrospective pooled analysis.

Authors:  Noriyuki Okonogi; Mai Fukahori; Masaru Wakatsuki; Yu Ohkubo; Shingo Kato; Yuhei Miyasaka; Hiroshi Tsuji; Takashi Nakano; Tadashi Kamada
Journal:  Radiat Oncol       Date:  2018-06-25       Impact factor: 3.481

4.  Percutaneous parametrial dose escalation in women with advanced cervical cancer: feasibility and efficacy in relation to long-term quality of life.

Authors:  Sati Akbaba; Jan Tobias Oelmann-Avendano; Tilman Bostel; Harald Rief; Nils Henrik Nicolay; Juergen Debus; Katja Lindel; Robert Foerster
Journal:  Radiol Oncol       Date:  2018-09-11       Impact factor: 2.991

5.  A single-institution review of image-guided brachytherapy for vaginal malignancies using customized molded applicators and interstitial needles.

Authors:  Emily Flower; Salman Zanjani; Gemma Busuttil; Emma Sullivan; Wayne Smith; Kathy Tran; David Thwaites; Jennifer Chard; Viet Do
Journal:  J Contemp Brachytherapy       Date:  2021-12-30

6.  Carbon Ion Radiotherapy for Locally Recurrent Rectal Cancer of Patients with Prior Pelvic Irradiation.

Authors:  Shigeru Yamada; Hirotoshi Takiyama; Yuka Isozaki; Makoto Shinoto; Daniel K Ebner; Masashi Koto; Hiroshi Tsuji; Hideaki Miyauchi; Mitsugu Sekimoto; Hideki Ueno; Michio Itabashi; Masataka Ikeda; Hisahiro Matsubara
Journal:  Ann Surg Oncol       Date:  2021-10-18       Impact factor: 5.344

7.  High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events.

Authors:  Kara D Romano; Colin Hill; Daniel M Trifiletti; M Sean Peach; Bethany J Horton; Neil Shah; Dylan Campbell; Bruce Libby; Timothy N Showalter
Journal:  Radiat Oncol       Date:  2018-07-16       Impact factor: 3.481

8.  Radiomics Analysis of 3D Dose Distributions to Predict Toxicity of Radiotherapy for Cervical Cancer.

Authors:  François Lucia; Vincent Bourbonne; Dimitris Visvikis; Omar Miranda; Dorothy M Gujral; Dominique Gouders; Gurvan Dissaux; Olivier Pradier; Florent Tixier; Vincent Jaouen; Julien Bert; Mathieu Hatt; Ulrike Schick
Journal:  J Pers Med       Date:  2021-05-11

9.  The Relationship Between Late Morbidity and Dose-Volume Parameter of Rectum in Combined Intracavitary/Interstitial Cervix Cancer Brachytherapy: A Mono-Institutional Experience.

Authors:  Ning Zhang; Ying Liu; Dongmei Han; Xin Guo; Zhuang Mao; Wei Yang; Guanghui Cheng
Journal:  Front Oncol       Date:  2021-07-23       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.